Equillium, Inc.

What they do

Equillium is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders. Its primary goal is to advance EQ504, a novel AhR modulator, into and through clinical development. The company has not yet generated product sales and has funded operations primarily through private placements of equity securities. As of June 30, 2026, it had an accumulated deficit of $226.2 million.

Revenue drivers

• No product revenue — The company has not generated product sales; historically reported revenue has come from collaboration or license agreements, but no current product revenue is described in the excerpts.
• EQ504 — Lead candidate, an AhR modulator, targeted for ulcerative colitis and potentially inflammatory lung diseases; no revenue to date.
• EQ302 — Oral bi-specific inhibitor of IL-15 and IL-21 in IND-enabling development for celiac disease; no revenue to date.

Recent performance

For the second quarter of 2026, Equillium reported a net loss of $4.7 million, or $(0.04) per basic and diluted share, compared with a net loss of $5.7 million, or $(0.16) per share, for the same period in 2025. R&D expenses were $2.8 million, down from $4.1 million in the prior-year period, while G&A expenses were $2.4 million, up from $2.1 million. Cash and cash equivalents totaled $57.2 million as of June 30, 2026, compared with $61.3 million as of March 31, 2026.

Strategy

Equillium's stated strategy is to advance EQ504 through a Phase 1 proof-of-mechanism study expected to initiate in the fourth quarter of 2026, with topline data anticipated approximately six months thereafter. The study is designed as a randomized, double-blind, placebo-controlled single and multiple ascending dose study in healthy volunteers. Subject to supportive data, the company plans to initiate a placebo-controlled study in patients with moderately to severely active ulcerative colitis. It has also initiated IND-enabling development activities for EQ504 as a potential inhaled therapy for inflammatory lung diseases and for EQ302 in celiac disease. A Clinical Advisory Board chaired by Professor Bruce Sands was established to guide the EQ504 ulcerative colitis program.

Risks

• No product revenue and history of losses — Equillium has not generated product sales and had an accumulated deficit of $226.2 million as of June 30, 2026, with expected additional losses.
• Clinical development risk — The company's lead candidate EQ504 has not yet entered Phase 1; the study is expected to initiate in Q4 2026, and data may not be favorable.
• Need for additional capital — Management expects to incur additional losses and will need to raise additional capital to implement its research and development plans.
• Dependence on key candidates — The company's prospects depend heavily on EQ504, which is still preclinical or early clinical, and on other early-stage programs like EQ302.

Outlook

Management expects to initiate a Phase 1 proof-of-mechanism study for EQ504 in the fourth quarter of 2026 and report topline data approximately six months thereafter. The company believes its cash and cash equivalents as of June 30, 2026, are sufficient to fund planned operations into 2029. Subject to supportive Phase 1 data, it anticipates initiating a placebo-controlled efficacy study in ulcerative colitis patients.